PRIMA’s Centre Director Karl-Johan Malmberg receive FRIPRO-funding from the Research council of Norway to enhance the therapeutic potential of NK cells for off-the-shelf cell therapy towards cancer.
Lamberto Torralba Raga, one of PRIMA’s young scientists, has been awarded 2 million NOK from the Research Council of Norway’s newly launched Radical Research Ideas scheme. His project, ECHO: Epigenetic Cellular Hack for Oncotherapy, aims to develop a new generation of “smart immune cells” capable of transforming cancer treatment.
PRIMA group leader June Myklebust, together with Professors Kjetil Taskén and Ludvig Sollid, published an opinion piece in Aftenposten outlining the scientific discoveries that led to the 2025 Nobel Prize in Physiology or Medicine for the identification of regulatory T cells and emphasize the importance of basic research.
The researchers are studying the role of mitophagy in cancer development and how NK cells and antibodies can be utilised in cancer treatment.
Biology students from Akademiet Realfagsgymnas Sandvika on a “field” trip to Olweus’s lab to learn more about biotechnology
Following the nominations for the 2025 election, Olweus has been elected as a Fellow of the European Academy of Cancer Sciences (EACS). This is a prestigious recognition of outstanding contributions to cancer research and oncology.
Get to know Sigrid Fu Skjelbostad in the Haapaniemi Lab who started her PhD in September!
We are thrilled to announce that PRIMA researchers have been awarded five significant research grants from the Norwegian Cancer Society in this year’s funding round.
To survive, cancer cells must evade detection by the immune system. However, researchers have found ways to reprogram immune cells so they can effectively recognize and eliminate these cancer cells while sparing the surrounding healthy tissue. This concept is explained clearly and engagingly by Johanna Olweus in her blog at "Medisinbloggen" at the Medical Faculty of the University of Oslo.
We are proud to announce that PRIMA researcher Chloe B. Steen has been selected as a new member of the Young Academy of Norway (AYF) for the period 2025–2029.
Antibiotic resistance is a growing challenge to global health, and there is an urgent need to develop new ways to combat bacteria that no longer respond to conventional treatments. As part of her PhD project, Mirjam Dürkoop is designing custom-made antibodies that may open up entirely new possibilities for therapy.
Evolution has produced one of the most sophisticated libraries for drug discovery—the T-cell receptor repertoire! This Nature Reviews Cancer Perspective explores how it could be deployed against myeloid cancers, particularly the cells that sustain them.
Get to know Markus Kanduth in the Olweus Lab! Kanduth was recruited to PRIMA in the spring and started his PhD position in August
How can T cells that recognize mutations inside cancer cells cure patients who currently lack treatment options? Listen to the latest episode of the HealthTalk podcast.
The Swedish Childhood Cancer Fund has interviewed PRIMA scientists Malmberg and Sohlberg on the development of their new cell therapy with Natural Killer cells
Superio Bio is a new Norwegian biotech company with academic roots in PRIMA, building on long-term academic research from Jan Terje Andersen’s lab.
Victor Greiff and Fridtjof Lund-Johansen have been named Innovators of the Year 2025 by Inven2 for their pioneering work at the intersection of artificial intelligence and antibody-based drug development. Their research exemplifies how computational biology and immunology can converge to accelerate therapeutic innovation.
Dr. Aaron Newman from Stanford University is a Visiting Professor at PRIMA and will be visiting the Centre August 25-29, 2025
The two Norwegian Centres of Excellence, PRIMA and CanCell, have joined forces and offer a common mentor pool to advise postdocs/researchers within the Centres.
PhD student Herman Netskar receives the prize for his Nature Immunology paper “Pan-cancer profiling of tumor-infiltrating natural killer cells through transcriptional reference mapping”
Ebba Sohlberg and Karl-Johan Malmberg from PRIMA wrote a News & Views article for Nature Medicine, highlighting groundbreaking results from a clinical trial treating patients with refractory Hodgkin lymphoma using natural killer (NK) cells combined with NK cell-specific engagers.
Jan Terje Andersen’s research group has published a new study on a nasal spray vaccine that offers protection against respiratory viruses. The concept is now ready for further development and human testing.
Translation dysregulation in cancer produces targetable antigens
Check out our report detailing the first 18 months of progress in PRIMA
PI Jan Terje Andersen holds an Distinguished Innovator grant and is an innovation ambassador at the Novo Nordisk Foundation. Recently he attended a Networking Event where over 30 Distinguished Innovators from across the Nordics came together to share their experiences and foster collaborations.
